Categories: News

Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) will be held virtually via live webcast on Thursday, June 16, 2022 at 10:00 am EDT. Stockholders of record as of the close of business on April 18, 2022, are entitled to vote at the Annual Meeting.

As provided in the Company’s proxy materials, an online portal is available to stockholders at https://www.proxyvote.com where stockholders can view and download the Company’s proxy materials and 2021 Annual Report and vote their shares in advance of the Annual Meeting. Stockholders are asked to vote by 11:59 pm EDT on Wednesday, June 15, 2022. For shares held in a plan, stockholders are asked to vote by 11:59 pm EDT on Monday, June 13, 2022.

To be admitted to the Annual Meeting, stockholders must register at www.virtualshareholdermeeting.com/EYEN2022 by 9:45 am EDT on June 16, 2022. To register, stockholders must enter their control number found in the proxy materials sent to stockholders. Eyenovia encourages stockholders to access the Annual Meeting prior to the start time in order to allow ample time for check-in procedures.

Whether or not a stockholder plans to attend the virtual-only Annual Meeting, Eyenovia urges each stockholder to vote and submit their proxy in advance of the meeting by one of the methods described in the proxy materials.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

Staff

Recent Posts

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage…

1 hour ago

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the…

1 hour ago

Unique Treatment for BPH, Chronic Prostatitis, Back Pain and Kidney Stones Was Unveiled at Arab Health 2024 by Ariana Adjani

* Efficacy, safety, and cost-effectiveness of Thermobalancing therapy and Dr Allen's Devices were showcased at…

22 hours ago

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

2 days ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

2 days ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

2 days ago